Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab

A 36-year-old woman with no medical or surgical history was evaluated for weight loss. Abdominal computed tomography (CT) showed signs of Crohn's disease, which was later confirmed endoscopically. She was started on tumor necrosis factor-α (TNF-α) inhibitor therapy. Nine months after treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelqader, Abdelhai, Goud, Aditya, Fleisher, Albert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843151/
https://www.ncbi.nlm.nih.gov/pubmed/27144199
http://dx.doi.org/10.14309/crj.2016.44
_version_ 1782428637004300288
author Abdelqader, Abdelhai
Goud, Aditya
Fleisher, Albert S.
author_facet Abdelqader, Abdelhai
Goud, Aditya
Fleisher, Albert S.
author_sort Abdelqader, Abdelhai
collection PubMed
description A 36-year-old woman with no medical or surgical history was evaluated for weight loss. Abdominal computed tomography (CT) showed signs of Crohn's disease, which was later confirmed endoscopically. She was started on tumor necrosis factor-α (TNF-α) inhibitor therapy. Nine months after treatment, she experienced additional weight loss and a 7 x 8 x 8-cm mass on repeat CT. Biopsy revealed retroperitoneal fibromatosis, so TNF-α was continued. Repeat CT showed an enlarged mass. TNF-α therapy had a suspected role in mass growth, therapy was discontinued, and the mass surgically resected. One year after resection, she has regained weight with no recurrence of the mesenteric fibromatosis.
format Online
Article
Text
id pubmed-4843151
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-48431512016-05-03 Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab Abdelqader, Abdelhai Goud, Aditya Fleisher, Albert S. ACG Case Rep J Case Report A 36-year-old woman with no medical or surgical history was evaluated for weight loss. Abdominal computed tomography (CT) showed signs of Crohn's disease, which was later confirmed endoscopically. She was started on tumor necrosis factor-α (TNF-α) inhibitor therapy. Nine months after treatment, she experienced additional weight loss and a 7 x 8 x 8-cm mass on repeat CT. Biopsy revealed retroperitoneal fibromatosis, so TNF-α was continued. Repeat CT showed an enlarged mass. TNF-α therapy had a suspected role in mass growth, therapy was discontinued, and the mass surgically resected. One year after resection, she has regained weight with no recurrence of the mesenteric fibromatosis. American College of Gastroenterology 2016-04-15 /pmc/articles/PMC4843151/ /pubmed/27144199 http://dx.doi.org/10.14309/crj.2016.44 Text en Copyright © Abdelqader et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Abdelqader, Abdelhai
Goud, Aditya
Fleisher, Albert S.
Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
title Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
title_full Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
title_fullStr Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
title_full_unstemmed Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
title_short Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
title_sort mesenteric fibromatosis in crohn's disease as a potential effect of adalimumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843151/
https://www.ncbi.nlm.nih.gov/pubmed/27144199
http://dx.doi.org/10.14309/crj.2016.44
work_keys_str_mv AT abdelqaderabdelhai mesentericfibromatosisincrohnsdiseaseasapotentialeffectofadalimumab
AT goudaditya mesentericfibromatosisincrohnsdiseaseasapotentialeffectofadalimumab
AT fleisheralberts mesentericfibromatosisincrohnsdiseaseasapotentialeffectofadalimumab

Ejemplares similares